


BRL-15572 dihydrochloride

Chemical Properties

CAS No. :	193611-72-2
Formula:	C ₂₅ H ₂₇ ClN ₂ O·2HCl
Molecular Weight:	479.87
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	BRL-15572 dihydrochloride (BRL 15573 dihydrochloride) is a 5-HT _{1D} receptor antagonist with pK _i of 7.9, also shows a considerable affinity at 5-HT _{1A} and 5-HT _{2B} receptors, exhibiting 60-fold selectivity over 5-HT _{1B} receptor.
Targets(IC ₅₀)	5-HT Receptor
In vitro	BRL-15572 displays high affinity and selectivity for h5-HT _{1D} receptors. BRL-15572 has 60-fold higher affinity for h5-HT _{1D} than 5-HT _{1B} receptors. BRL-15572 binds to h5-HT _{1B} and h5-HT _{1D} receptors with pK _B of less than 6 and 7.1, respectively. BRL-15572 stimulates [35S]GTP γ S binding in both cell lines, with potencies that correlated with their receptor binding affinities in both h5-HT _{1B} and h5-HT _{1D} receptor expressing cell lines. BRL-15572 reveals receptor binding affinities for 5-HT _{1A} , 5-HT _{1B} , 5-HT _{1E} , 5-HT _{1F} , 5-HT _{2A} , 5-HT _{2B} , 5-HT _{2C} , 5-HT ₆ and 5-HT ₇ with pK _i of 7.7, 6.1, 5.2, 6.0, 6.6, 7.4, 6.2, 5.9 and 6.3, respectively. In the h5-HT _{1D} cell line, both BRL-15572 (1 μM) shifts the 5-HT concentration response curve with pK _B of 7.1, respectively. BRL-15572 does have moderately high affinity at human 5-HT _{1A} and 5-HT _{2B} receptors. [1] In human atrial appendages, the electrically evoked tritium overflow is inhibited by 5-HT in a manner susceptible to antagonism by BRL-15572 (300 nM; 23 times K _i at h5-HT _{1D} receptors). [2] The inhibitory effect of 5-HT on the K ⁺ -evoked overflow of glutamate is antagonized by the h5-HT _{1D} receptor ligand BRL-15572. BRL-15572 (1 μM) is unable to modify the effect of 5-HT at the autoreceptor regulating [3H]5-HT release. [3] The selective 5-HT _{1D} /1B receptor antagonist BRL 15572 inhibits the effect of the agonist L-694 247. [4]
In vivo	In diabetic pithed rats, administration of the selective 5-HT _{1D} receptor antagonist BRL-15572 (2 mg/kg) does not modify the decreased HR induced by vagal electrical stimulation. The effects of L-694,247 (50 μg/kg), a selective agonist for non-rodent 5-HT _{1B} and 5-HT _{1D} receptors, on the vagally induced bradycardia are not apparent after pretreatment with BRL-15572. [5]
Cell Research	[35S]GTPγS binding studies. [35S]GTPγS binding studies in CHO cells expressing the h5-HT _{1B} or h5-HT _{1D} receptors are performed. In brief, membranes from 1 × 10 ⁶ cells are preincubated at 30°C for 30 minutes, in HEPES buffer (HEPES [20 mM], MgCl ₂ [3 mM], NaCl [100 mM], ascorbate [0.2 mM]), containing GDP (10 μM), with or without BRL-15572. The reaction is started by the addition of 10 μL of [35S]GTPγS (100 pM, assay concentration) followed by a further 30 minutes incubation at 30°C. Non-specific binding is determined by addition of unlabelled GTPγS (10 μM), prior to the addition of cells. The reaction is stopped by rapid filtration using Whatman GF/B grade filters followed by five

A DRUG SCREENING EXPERT

Cell Research	washes with ice-cold HEPES buffer. Radioactivity is determined by liquid scintillation spectrometry.(Only for Reference)
---------------	--

Solubility Information

Solubility	DMSO: 89 mg/mL (185.47 mM),Sonication is recommended. H2O: < 1 mg/mL (insoluble or slightly soluble), Ethanol: 38 mg/mL (79.19 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 3.3 mg/mL (6.88 mM),Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.0839 mL	10.4195 mL	20.839 mL
5 mM	0.4168 mL	2.0839 mL	4.1678 mL
10 mM	0.2084 mL	1.0419 mL	2.0839 mL
50 mM	0.0417 mL	0.2084 mL	0.4168 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

- Price GW, et al. Naunyn Schmiedebergs Arch Pharmacol. 1997, 356(3), 312-320.
Schlicker E, et al. Naunyn Schmiedebergs Arch Pharmacol. 1997, 356(3), 321-327.
Marcoli M, et al. Br J Pharmacol. 1999, 126(3), 607-612.
Calama E, et al. Clin Exp Pharmacol Physiol. 2005, 32(10), 894-900.
García M, et al. Clin Exp Pharmacol Physiol. 2007 Nov;34(11):1199-206.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only· Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481